The Weizmann Institute in Rehovot and its commercial arm, the Yeda Research and Development company has announced a multi-year deal with Pfizer Pharmaceuticals’ Global Research division, to explore areas of research that may not be as often addressed in the United States.
The agreement, made public on Monday (June 6), involves collaboration at the newly-established National Drug Discovery Institute (DDI) – located at the Weizmann Institute – in the Nancy and Steven Grand Israel National Center for Personalized Medicine (G-INCPM).
The center will work on projects of mutual interest, in particular those that might address unmet medical needs.
“This is an exciting partnership for Pfizer,” said Mikael Dolsten, President of Pfizer Global Research.
“We have interacted with the Weizmann Institute for many years and have confidence in their scientific vision and expertise. We anticipate that this arrangement could potentially result in meaningful discoveries in the coming years,” he added.
For projects that appear to have further potential, Pfizer and Yeda said they would discuss research and development agreements.
